The DOI matches its Crossref record; 153 of the 153 references it cites were found in a registry or an index.
Serotonin–dopamine interaction: electrophysiological evidence
Abstract
In this review, the most relevant data regarding serotonin (5-hydroxytryptamine, 5-HT)/dopamine (DA) interaction in the brain, as studied by both in vivo and in vitro electrophysiological methods, are reported and discussed. The bulk of neuroanatomical data available clearly indicate that DA-containing neurons in the brain receive a prominent innervation from 5-HT originating in the raphe nuclei of the brainstem. Furthermore, this modulation seems to be reciprocal; DA neurons innervate the raphe nuclei and exert a tonic excitatory effect on them. Compelling electrophysiological data show that 5-HT can exert complex effects on the electrical activity of midbrain DA neurons mediated by the various receptor subtypes. The main control seems to be inhibitory, this effect being more marked in the ventral tegmental area (VTA) as compared to the substantia nigra pars compacta (SNc). In spite of a direct effect of 5-HT by its receptors located on DA cells, 5-HT can modulate their activity indirectly, modifying gamma-amino-n-butyric acid (GABA)-ergic and glutamatergic input to the VTA and SNc. Although 5-HT/DA interaction in the brain has been extensively studied, much work remains to be done to clarify this issue. The recent development of subtype-selective ligands for 5-HT receptors will not only allow a detailed understanding of this interaction but also lead to development of new treatment strategies, appropriate for those neuropsychiatric disorders in which an alteration of the 5-HT/DA balance is supposed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Serotonergic and dopaminergic markers are jointly present in their developmental origins, guidepost areas, as well as within the subdomains of the PFC, which is important for their intricate interaction later in life to establish higher cognitive functions [209, 232–234].”
From Development of prefrontal cortex (2022) · cites this paper as [233]
Citations
Cites
A review of central 5-HT receptors and their function
Barnes, N. M., & Sharp, T. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(99)00010-6 · Cited by 3,211
International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin).
Hoyer, D., Clarke, D. E., Fozard, J. R., Hartig, P. R., Martin, G. R., Mylecharane, E. J., Saxena, P. R., & Humphrey, P. P. A. (1994) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06783-3 · Cited by 3,025
Steinbusch, H. W. M. (1981) · Neuroscience · doi:10.1016/0306-4522(81)90146-9 · Cited by 2,415
Azmitia, E. C., & Segal, M. (1978) · The Journal of Comparative Neurology · doi:10.1002/cne.901790311 · Cited by 1,908
Molecular, pharmacological and functional diversity of 5-HT receptors
Hoyer, D., Hannon, J. P., & Martin, G. R. (2002) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(01)00746-8 · Cited by 1,898
Pazos, Á., & Palacios, J. M. (1985) · Brain Research · doi:10.1016/0006-8993(85)90856-x · Cited by 1,855
Evidence for the existence of monoamine neurons in the central nervous system
Fuxé, K. (1965) · Cell and Tissue Research · doi:10.1007/bf00337069 · Cited by 1,567
Fuxé, K. (1965) · PubMed · Cited by 1,544
The control of firing pattern in nigral dopamine neurons: burst firing
Grace, A., & Bunney, B. (1984) · Journal of Neuroscience · doi:10.1523/jneurosci.04-11-02877.1984 · Cited by 1,346
Efferent connections of the substantia nigra and ventral tegmental area in the rat
Beckstead, R. M., Domesick, V. B., & Nauta, W. J. H. (1979) · Brain Research · doi:10.1016/0006-8993(79)91001-1 · Cited by 1,293
Cited by
Sorted by citations
International society of sports nutrition position stand: caffeine and performance
Goldstein, E. R., Ziegenfuss, T., Kalman, D., Kreider, R., Campbell, B., Wilborn, C., Taylor, L., Willoughby, D., Stout, J., Graves, B. S., et al. (2010) · Journal of the International Society of Sports Nutrition · doi:10.1186/1550-2783-7-5 · Cited by 686
International Society of Sports Nutrition Position Stand: Caffeine and Exercise Performance
Guest, N. S., VanDusseldorp, T. A., Nelson, M. T., Grgic, J., Schoenfeld, B. J., Jenkins, N. D. M., Arent, S. M., Antonio, J., Stout, J. R., Trexler, E. T., et al. (2021) · Journal of the International Society of Sports Nutrition · doi:10.1186/s12970-020-00383-4 · Cited by 665
Development of prefrontal cortex
Kolk, S. M., & Rakic, P. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-021-01137-9 · Cited by 378
VLAAMS DIERGENEESKUNDIG TIJDSCHRIFT
Vermeire, S., Audenaert, K., Vandermeulen, E., Mees, R. D., van Bree, H., Dobbeleir, A. A., Peremans, K. Y., De, R., Declercq, A., Maes, S., et al. (2011) · Cited by 297
Hale, M. W., Shekhar, A., & Lowry, C. A. (2012) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-012-9827-1 · Cited by 220
Wang, H.-L., Zhang, S., Qi, J., Wang, H., Cachope, R., Mejias-Aponte, C. A., Gomez, J. A., Mateo-Semidey, G. E., Beaudoin, G. M. J., Paladini, C. A., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.01.014 · Cited by 176
Modulating the Neuromodulators: Dopamine, Serotonin, and the Endocannabinoid System
Peters, K. Z., Cheer, J. F., & Tonini, R. (2021) · Trends in Neurosciences · doi:10.1016/j.tins.2021.02.001 · Cited by 180
Deurwaerdère, P. D., & Giovanni, G. D. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.03.004 · Cited by 170
Dopamine–serotonin interactions in attention-deficit hyperactivity disorder (ADHD)
Oades, R. D. (2008) · Progress in brain research · doi:10.1016/s0079-6123(08)00926-6 · Cited by 167
Multiple Modes of Impulsivity in Parkinson's Disease
Nombela, C., Rittman, T., Robbins, T. W., & Rowe, J. B. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085747 · Cited by 142
Transcranial direct-current stimulation increases extracellular dopamine levels in the rat striatum
Tanaka, T., Takano, Y., Tanaka, S., Hironaka, N., Kobayashi, K., Hanakawa, T., Watanabe, K., & Honda, M. (2013) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2013.00006 · Cited by 125
“The extracellular serotonin level in the striatum was also measured, as it is known to be associated with the dopamine level (Di Giovanni et al., 2008; Navailles and De Deurwaerdere, 2011).”
BackgroundParker, M. O., Brock, A. J., Walton, R. T., & Brennan, C. H. (2013) · Frontiers in Neural Circuits · doi:10.3389/fncir.2013.00063 · Cited by 133
Early Life Stress, Depression And Parkinson’s Disease: A New Approach
Dallé, E., & Mabandla, M. V. (2018) · Molecular Brain · doi:10.1186/s13041-018-0356-9 · Cited by 131
Darmani, N. A., & Ray, A. P. (2009) · Chemical Reviews · doi:10.1021/cr900117p · Cited by 110
The role of the serotonergic system at the interface of aggression and suicide
Bortolato, M., Pivac, N., Šeler, D. M., Perković, M. N., Pessia, M., & Giovanni, G. D. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.01.015 · Cited by 118
Baumann, M. H., Clark, R. D., Woolverton, W. L., Wee, S., Blough, B. E., & Rothman, R. B. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.176271 · Cited by 110
Presynaptic control of serotonin on striatal dopamine function
Navailles, S., & Deurwaerdère, P. D. (2010) · Psychopharmacology · doi:10.1007/s00213-010-2029-y · Cited by 109
Motor and nonmotor complications in Parkinson’s disease: an argument for continuous drug delivery?
Chaudhuri, К. R., Rizos, A., & Sethi, K. D. (2013) · Journal of Neural Transmission · doi:10.1007/s00702-013-0981-5 · Cited by 104
Zheng, X., An, K., Dai, C., Liang, Y. L., Xie, T., Xie, L. Y., Peng, Y., Wang, G., & Hao, H. (2012) · Analytical Chemistry · doi:10.1021/ac3025202 · Cited by 105
A review of the role of serotonin system genes in obsessive-compulsive disorder
Sinopoli, V. M., Burton, C. L., Kronenberg, S., & Arnold, P. D. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.05.029 · Cited by 107
Persistent Adaptations in Afferents to Ventral Tegmental Dopamine Neurons after Opiate Withdrawal
Kaufling, J., & Aston‐Jones, G. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.0715-15.2015 · Cited by 89
Guiard, B. P., Mansari, M. E., & Blier, P. (2009) · Current Drug Targets · doi:10.2174/138945009789735156 · Cited by 99
Emotional dysfunction in Parkinson's disease.
Blonder, L. X., & Slevin, J. T. (2011) · PubMed Central · doi:10.3233/ben-2011-0329 · Cited by 86
Light-sensitive brain pathways and aging
Daneault, V., Dumont, M., Massé, É., Vandewalle, G., & Carrier, J. (2016) · Journal of PHYSIOLOGICAL ANTHROPOLOGY · doi:10.1186/s40101-016-0091-9 · Cited by 86
Current animal models of obsessive compulsive disorder: an update
Albelda, N., & Joel, D. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.08.070 · Cited by 85
Nikolic, K. M., Mavridis, L., Djikić, T., Vučićević, J., Agbaba, D. D., Yelekçi, K., & Mitchell, J. B. O. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00265 · Cited by 79
Role for serotonin2A (5-HT2A) and 2C (5-HT2C) receptors in experimental absence seizures
Venzi, M., David, F., Bellet, J., Cavaccini, A., Bombardi, C., Crunelli, V., & Giovanni, G. D. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.04.016 · Cited by 72
Glycogen Synthase Kinase-3 is an Intermediate Modulator of Serotonin Neurotransmission
Polter, A. M., & Li, X. (2011) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2011.00031 · Cited by 70
Polypharmacology of dopamine receptor ligands
Butini, S., Nikolic, K. M., Kassel, S., Brückmann, H., Filipić, S., Agbaba, D. D., Gemma, S., Brogi, S., Brindisi, M., Campiani, G., et al. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.03.011 · Cited by 69
Scheunemann, L., Plaçais, P.-Y., Dromard, Y., Schwärzel, M., & Préat, T. (2018) · Neuron · doi:10.1016/j.neuron.2018.03.032 · Cited by 72
The Formation and Function of the VTA Dopamine System
Hou, G., Hao, M., Duan, J., & Han, M.-H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073875 · Cited by 65
Jaunarajs, K. L. E., George, J. A., & Bishop, C. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.05.052 · Cited by 65
The Engagement of Cytochrome P450 Enzymes in Tryptophan Metabolism
Haduch, A., Bromek, E., Kuban, W., & Daniel, W. A. (2023) · Metabolites · doi:10.3390/metabo13050629 · Cited by 63
Serotonin excites fast‐spiking interneurons in the striatum
Blomeley, C. P., & Bracci, E. (2009) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2009.06725.x · Cited by 62
Aging Reduces the Stimulating Effect of Blue Light on Cognitive Brain Functions
Daneault, V., Hébert, M., Albouy, G., Doyon, J., Dumont, M., Carrier, J., & Vandewalle, G. (2014) · SLEEP · doi:10.5665/sleep.3314 · Cited by 64
Increased local dopamine secretion has growth‐promoting effects in cholangiocarcinoma
Coufal, M., Invernizzi, P., Gaudio, E., Bernuzzi, F., Frampton, G. A., Onori, P., Franchitto, A., Carpino, G., Ramirez, J. C., Alvaro, D., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.24909 · Cited by 60
Schilman, E. A., Klavir, O., Winter, C., Sohr, R., & Joel, D. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.208 · Cited by 55
Delaville, C., Navailles, S., & Benazzouz, A. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.11.024 · Cited by 55
Clark, P., Amat, J., McConnell, S. O., Ghasem, P. R., Greenwood, B. N., Maier, S. F., & Fleshner, M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0141898 · Cited by 53
Additive effects of serotonergic and dopaminergic polymorphisms on trait impulsivity
Varga, G., Székely, A., Antal, P., Sárközy, P., Nemoda, Z., Demetrovics, Z., & Sasvári‐Székely, M. (2012) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32025 · Cited by 52
A Review of Transcranial Magnetic Stimulation in Vascular Dementia
Pennisi, G., Ferri, R., Cantone, M., Lanza, G., Pennisi, M., Vinciguerra, L., Malaguarnera, G., & Bella, R. (2011) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000322798 · Cited by 51
Demireva, E. Y., Suri, D., Morelli, E., Mahadevia, D., Chuhma, N., Teixeira, C. M., Ziolkowski-Blake, A., Hersh, M. A., Fifer, J. E., Bagchi, S., et al. (2018) · Molecular Psychiatry · doi:10.1038/s41380-018-0227-x · Cited by 52
Orbán, G., Bombardi, C., Marino, A., Colangeli, R., Pierucci, M., Pomara, C., Pessia, M., Bucchieri, F., Benigno, A., Smolders, I. J., et al. (2014) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12285 · Cited by 46
Self-citationHaduch, A., & Daniel, W. A. (2018) · Drug Metabolism Reviews · doi:10.1080/03602532.2018.1554674 · Cited by 45
Restless legs syndrome: Over 50 years of E uropean contribution
Khachatryan, S. G., Ferri, R., Fulda, S., Garcı́a-Borreguero, D., Manconi, M., Muntean, M., & Stefani, A. (2022) · Journal of Sleep Research · doi:10.1111/jsr.13632 · Cited by 41
Balasubramani, P. P., Chakravarthy, V. S., Ravindran, B., & Moustafa, A. A. (2014) · Frontiers in Computational Neuroscience · doi:10.3389/fncom.2014.00047 · Cited by 44
Haleem, D. J. (2014) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000123 · Cited by 41
Prinz, A., Selesnew, L.-M., Liss, B., Roeper, J., & Carlsson, T. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2013.06.015 · Cited by 38
The Psychopharmacology of Obsessive-Compulsive Disorder: A Preclinical Roadmap
Szechtman, H., Harvey, B. H., Woody, E. Z., & Hoffman, K. L. (2019) · Pharmacological Reviews · doi:10.1124/pr.119.017772 · Cited by 41
The dopaminergic system and Alzheimer’s disease
Zhang, Y., Liang, Y., & Gu, Y. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-00230 · Cited by 47
Karanges, E. A., Li, K. M., Motbey, C. P., Callaghan, P. D., Katsifis, A. G., & McGregor, I. S. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s146114571100006x · Cited by 39
Haduch, A., Bromek, E., Kot, M., Kamińska, K., Gołembiowska, K., & Daniel, W. A. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13031 · Cited by 38
Melatonin Supports CYP2D-Mediated Serotonin Synthesis in the Brain
Haduch, A., Bromek, E., Wójcikowski, J., Gołembiowska, K., & Daniel, W. A. (2016) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.067413 · Cited by 38
Hoertel, N., Cipel, H., Blanco, C., Oquendo, M. A., Ellul, P., Leaune, É., Limosin, F., Peyre, H., & Costemale-Lacoste, J.-F. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.01.045 · Cited by 37
HTR1B as a risk profile maker in psychiatric disorders: a review through motivation and memory
Drago, A., Alboni, S., Brunello, N., Ronchi, D. D., & Serretti, A. (2009) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-009-0724-6 · Cited by 36
Katz, N., Guiard, B. P., Mansari, M. E., & Blier, P. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881109348178 · Cited by 35
Association of Cigarette Smoking with Sleep Disturbance and Neurotransmitters in Cerebrospinal Fluid
Li, H., Liu, Y., Xing, L., Yang, X., Xu, J., Ren, Q., Su, K., Lu, Y., & Wang, F. (2020) · Nature and Science of Sleep · doi:10.2147/nss.s272883 · Cited by 36
Impact of Serotonin (5-HT)2C Receptors On Executive Control Processes
Pennanen, L., van der Hart, M., Yu, L., & Tecott, L. H. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.258 · Cited by 33
Sternat, T., Fotinos, K., Fine, A., Epstein, I., & Katzman, M. A. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s170645 · Cited by 33
Can 5-HT3 antagonists contribute toward the treatment of schizophrenia?
Ellenbroek, B. A., & Prinssen, E. P. M. (2014) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000102 · Cited by 29
Kreiss, D. S., & Deurwaerdère, P. D. (2017) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2017.05.007 · Cited by 28
Zhang, K., Lu, J., & Yao, L. (2019) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2019.11.004 · Cited by 27
Hall, F. S., Sora, I., Hen, R., & Uhl, G. R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115009 · Cited by 28
Dombrovski, A. Y., Mulsant, B. H., Ferrell, R. E., Lotrich, F. E., Rosen, J., Wallace, M. J., Houck, P. R., Mazumdar, S., & Pollock, B. G. (2009) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e328333ee10 · Cited by 25
Pierre, C., Pradère, N., Froc, C., Ornelas‐García, C. P., Callebert, J., & Rétaux, S. (2020) · Journal of Experimental Biology · doi:10.1242/jeb.226092 · Cited by 25
Effect of paroxetine and bupropion on human resting brain perfusion: An arterial spin labeling study
Viviani, R., Abler, B., Seeringer, A., & Stingl, J. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2012.03.014 · Cited by 26
Brownley, K. A., Boettiger, C. A., Young, L., & Cefalu, W. T. (2015) · Medical Hypotheses · doi:10.1016/j.mehy.2015.03.020 · Cited by 26
Fletcher, P. J., Sinyard, J., & Higgins, G. A. (2010) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.07.002 · Cited by 25
Melo-Felippe, F. B., Andrade, J. B. D. S., Giori, I. G., Vieira-Fonseca, T., Fontenelle, L. F., & Kohlrausch, F. B. (2015) · Journal of Molecular Neuroscience · doi:10.1007/s12031-015-0697-0 · Cited by 28
Gendle, M. H., & Golding, A. C. (2010) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1139 · Cited by 24
Voigt, R. M., & Napier, T. C. (2012) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2011.00092 · Cited by 23
Predicting targets of compounds against neurological diseases using cheminformatic methodology
Nikolic, K. M., Mavridis, L., Bautista‐Aguilera, Ó. M., Marco‐Contelles, J., Stark, H., Carreiras, M. C., Rossi, I., Massarelli, P., Agbaba, D. D., Ramsay, R. R., et al. (2014) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-014-9816-1 · Cited by 22
Leg movements during sleep in children treated with serotonergic antidepressants
Ferri, R., Mogavero, M. P., Bruni, O., Picchietti, D. L., Kapoor, V., & DelRosso, L. M. (2021) · SLEEP · doi:10.1093/sleep/zsab236 · Cited by 22
Karanges, E. A., Kashem, M., Sarker, R., Ahmed, E. U., Ahmed, S., van Nieuwenhuijzen, P. V., Kemp, A., & McGregor, I. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00086 · Cited by 24
Bidirectional role of dopamine in learning and memory-active forgetting
Díaz, F. C., Caffino, L., & Fumagalli, F. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.10.011 · Cited by 24
Direct serotonin release in humans shapes aversive learning and inhibition
Colwell, M., Tagomori, H., Shang, F., Cheng, H. I., Wigg, C., Browning, M. D., Cowen, P. J., Murphy, S. E., & Harmer, C. J. (2024) · Nature Communications · doi:10.1038/s41467-024-50394-x · Cited by 21
Understanding Anhedonia: The Role of Perceived Control
MacAulay, R. K., McGovern, J. E., & Cohen, A. S. (2014) · Springer eBooks · doi:10.1007/978-94-017-8591-4_2 · Cited by 19
Acute Stress Exposure Alters Food-Related Brain Monoaminergic Profiles in a Rat Model of Anorexia
Reed, C. H., Bauer, E. E., Shoeman, A., Buhr, T. J., & Clark, P. (2021) · Journal of Nutrition · doi:10.1093/jn/nxab298 · Cited by 19
Jukić, M. M., Carrillo‐Roa, T., Bar, M., Becker, G., Jovanovic, V. M., Zega, K., Binder, E. B., & Brodski, C. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.244 · Cited by 20
Effect of Caffeine on Endurance Performance in Athletes May Depend on HTR2A and CYP1A2 Genotypes
Guest, N. S., Corey, P., Tyrrell, P. N., & El‐Sohemy, A. (2020) · The Journal of Strength and Conditioning Research · doi:10.1519/jsc.0000000000003665 · Cited by 19
Access to the CNS: Biomarker Strategies for Dopaminergic Treatments
van den Brink, W. J., Palić, S., Köhler, I., & de Lange, E. C. M. (2018) · Pharmaceutical Research · doi:10.1007/s11095-017-2333-x · Cited by 18
Worhunsky, P. D., Angarita, G. A., Zhai, Z. W., Matuskey, D., Gallezot, J., Malison, R. T., Carson, R. E., & Potenza, M. N. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-00874-7 · Cited by 18
Broadfoot, C. K., Lenell, C., Kelm‐Nelson, C. A., & Ciucci, M. R. (2022) · SSRN Electronic Journal · doi:10.1016/j.bbr.2022.114157 · Cited by 15
Antipsychotics and the Dopamine–Serotonin Connection
Ellenbroek, B. A., & Cesura, A. M. (2014) · Topics in medicinal chemistry · doi:10.1007/7355_2014_51 · Cited by 16
Zárate, R. V., Hidalgo, S., Navarro, N., Molina‐Mateo, D., Arancibia, D., Rojo-Cortés, F., Oliva, C., Andrés, M. E., Zamorano, P. L., & Campusano, J. M. (2022) · Cells · doi:10.3390/cells11091544 · Cited by 15
The h-Current in the Substantia Nigra pars Compacta Neurons: A Re-examination
Gambardella, C., Pignatelli, A., & Belluzzi, O. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052329 · Cited by 15
Antidepressants and Adolescent Brain Development
Karanges, E. A., & McGregor, I. S. (2011) · Future Neurology · doi:10.2217/fnl.11.51 · Cited by 16
Woody, E. Z., Hoffman, K. L., & Szechtman, H. (2019) · Advances in pharmacology · doi:10.1016/bs.apha.2019.04.003 · Cited by 16
Stępniowska, A., Drażbo, A. A., Kozłowski, K., Ognik, K., & Jankowski, J. (2019) · Animals · doi:10.3390/ani10010045 · Cited by 15
Imbalance between dopamine and serotonin caused by neonatal habenula lesion
Lee, Y., Kim, Y., Lee, J., Lee, S., & Goto, Y. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113316 · Cited by 14
Long-term administration of the antidepressant vilazodone modulates rat brain monoaminergic systems
Mansari, M. E., Crnic, A., Oosterhof, C. A., & Blier, P. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.09.007 · Cited by 14
Fletcher, P. J., Zeeb, F. D., Browne, C. J., Higgins, G. A., & Soko, A. D. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4529-5 · Cited by 14
Castle, M., & Flanigan, M. E. (2024) · Neurobiology of Stress · doi:10.1016/j.ynstr.2024.100618 · Cited by 13
Synaptic Interactions Between Serotonergic and Dopaminergic Systems in Parkinson’s Disease
Marino, G., Campanelli, F., Natale, G., Carluccio, M. D., Servillo, F., Ghiglieri, V., & Calabresi, P. (2025) · Current Neuropharmacology · doi:10.2174/011570159x336597241217062042 · Cited by 14
Brela, M. Z., Prah, A., Boczar, M., Stare, J., & Mavri, J. (2019) · Molecules · doi:10.3390/molecules24234359 · Cited by 13
In Vivo Microdialysis in Parkinson’s Research
Giovanni, G. D., Esposito, E., & Matteo, V. D. (2009) · Springer eBooks · doi:10.1007/978-3-211-92660-4_18 · Cited by 12
Self-citationBoulougouris, V., Malogiannis, I. A., Lockwood, G., Zervas, I. M., & Giovanni, G. D. (2013) · Experimental Brain Research · doi:10.1007/s00221-013-3669-z · Cited by 11
Igari, M., Shen, H., Hagino, Y., Fukushima, S., Kasahara, Y., Lesch, K., Murphy, D. L., Hall, F. S., Uhl, G. R., Ikeda, K., et al. (2014) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000120 · Cited by 12
Quand la saison devient synonyme de dépression
Gagné, A.-M., Bouchard, G., Tremblay, P., Sasseville, A., & Hébert, M. (2010) · médecine/sciences · doi:10.1051/medsci/201026179 · Cited by 11
Deurwaerdère, P. D., Casarrubea, M., Cassar, D., Radic, M., Puginier, E., Chagraoui, A., Crescimanno, G., Crunelli, V., & Giovanni, G. D. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.886033 · Cited by 10
Metadata
- Authors
- DIGIOVANNI, G., DIMATTEO, V, PIERUCCI, M., & ESPOSITO, E.
- Affiliations
- Mario Negri Institute for Pharmacological Research (IT)
- Corresponding author
- ESPOSITO, E
- ORCID
- PIERUCCI, M
- Venue
- Progress in Brain Research
- Publisher
- Elsevier
- Published
- 2008
- Volume
- 172
- Pages
- 45-71
- ISSN
- 0079-6123 (ISSN-L)
- OpenAlex
- W1554279409
- Cited by
- 151
- References
- 153
- Citations by year
- 2026: 7 · 2025: 3 · 2024: 5 · 2023: 5 · 2022: 6 · 2021: 10 · 2020: 6 · 2019: 10 · 2018: 7 · 2017: 5 · 2016: 10 · 2015: 9 · 2014: 15 · 2013: 10 · 2012: 10
- FWCI
- 12.85
- Type
- book chapter
- Language
- en
- Open access
- closed
- Locations
- Progress in brain research (publishedVersion)
- PubMed (publishedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Keywords
- serotonin-dopamine interaction, serotonin, dopaminergic neurons, raphe nuclei, ventral tegmental area, substantia nigra pars compacta, serotonin receptors, GABAergic input, glutamatergic input, neuropsychiatric disorders, subtype-selective ligands
- MeSH terms
- Animals, Brain, Dopamine, Electric Stimulation, Electrophysiology, Neural Pathways, Neurons, Receptors, Serotonin, Serotonin, Serotonin Antagonists, Serotonin Receptor Agonists, Selective Serotonin Reuptake Inhibitors, Dopamine Agonists, Dopamine Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review